Columbus, OH15 Active Studies

Alzheimers Disease Clinical Trials in Columbus, OH

Find 15 actively recruiting alzheimers disease clinical trials in Columbus, OH. Connect with local research sites and explore new treatment options.

15
Active Trials
15
Sponsors
2,318
Enrolling

Recruiting Alzheimers Disease Studies in Columbus

RecruitingColumbus, OHNCT05916339

AWARE: Management of ADHD in Autism Spectrum Disorder

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents wit...

500 participants
Daniel Coury
View Study Details
RecruitingColumbus, OHNCT06351631

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...

400 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingColumbus, OHNCT06062420

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) p...

360 participants
GlaxoSmithKline
View Study Details
RecruitingColumbus, OHNCT05684965

XTX301 in Patients With Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....

358 participants
Xilio Development, Inc.
View Study Details
RecruitingColumbus, OHNCT06950385

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compa...

168 participants
Rapamycin Holdings Inc.
View Study Details
RecruitingColumbus, OHNCT06657222

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To ...

130 participants
Tubulis GmbH
View Study Details
RecruitingColumbus, OHNCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adj...

100 participants
Reunion Neuroscience Inc
View Study Details
RecruitingColumbus, OHNCT05710848

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients wit...

75 participants
SURGE Therapeutics
View Study Details
RecruitingColumbus, OHNCT06161974

Study of Olutasidenib and Temozolomide in HGG

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation...

60 participants
Rigel Pharmaceuticals
View Study Details
RecruitingColumbus, OHNCT06060613

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors....

52 participants
Obsidian Therapeutics, Inc.
View Study Details
RecruitingColumbus, OHNCT06768671

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS....

35 participants
MoonLake Immunotherapeutics AG
View Study Details
RecruitingColumbus, OHNCT06943521

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced s...

27 participants
Mitsubishi Tanabe Pharma America Inc.
View Study Details
RecruitingColumbus, OHNCT06263153

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ci...

24 participants
Yuanquan Yang
View Study Details
RecruitingColumbus, OHNCT03266627

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents...

20 participants
New York Medical College
View Study Details
RecruitingColumbus, OHNCT06064890

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations...

9 participants
AviadoBio Ltd
View Study Details

About Alzheimers Disease Clinical Trials in Columbus

Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.

There are currently 15 alzheimers disease clinical trials recruiting participants in Columbus, OH. These studies are seeking a combined 2,318 participants. Research is being sponsored by Daniel Coury, Merck Sharp & Dohme LLC, GlaxoSmithKline and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Alzheimers Disease Clinical Trials in Columbus — FAQ

Are there alzheimers disease clinical trials in Columbus?

Yes, there are 15 alzheimers disease clinical trials currently recruiting in Columbus, OH. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Columbus?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbus research site will contact you about next steps.

Are clinical trials in Columbus free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Columbus studies also compensate for your time and travel.

What alzheimers disease treatments are being tested?

The 15 active trials in Columbus are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.

Data updated March 2, 2026 from ClinicalTrials.gov